The pathology of amyloidosis in classification: a review
MM Picken - Acta haematologica, 2020 - karger.com
Background: The amyloidoses are a rare and heterogeneous group of disorders that are
characterized by the deposition of abnormally folded proteins in tissues ultimately leading to …
characterized by the deposition of abnormally folded proteins in tissues ultimately leading to …
Amyloidosis: insights from proteomics
A Dogan - Annual Review of Pathology: Mechanisms of Disease, 2017 - annualreviews.org
Amyloidoses are a spectrum of disorders caused by abnormal folding and extracellular
deposition of proteins. The deposits lead to tissue damage and organ dysfunction …
deposition of proteins. The deposits lead to tissue damage and organ dysfunction …
LECT-2 amyloidosis: what do we know?
Amyloidosis is a rare group of diseases characterized by abnormal folding of proteins and
extracellular deposition of insoluble fibrils. It can be localized to one organ system or can …
extracellular deposition of insoluble fibrils. It can be localized to one organ system or can …
[HTML][HTML] Leukocyte cell‐derived chemotaxin‐2: it's role in pathophysiology and future in clinical medicine
BACKGROUND The discovery of leukocyte cell‐derived chemotaxin‐2 (LECT2) was the
result of a drive to find novel biomarkers of inflammatory diseases. 1 It was first isolated in …
result of a drive to find novel biomarkers of inflammatory diseases. 1 It was first isolated in …
Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico
CP Larsen, ML Beggs, JD Wilson, SL Lathrop - Amyloid, 2016 - Taylor & Francis
Abstract Leukocyte chemotactic factor 2 (LECT2) amyloidosis is one of the most recently
described types of amyloidosis. Since its description, it has been found to be one the most …
described types of amyloidosis. Since its description, it has been found to be one the most …
Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Distribution in a Mexican Population: An Autopsy Study
MA de la Cruz Jasso, JM Mejía-Vilet… - American Journal of …, 2023 - academic.oup.com
Objectives To assess the prevalence of leukocyte cell-derived chemotactic 2 (LECT2), its
organ involvement, and its clinical association in autopsies from an ethnically biased …
organ involvement, and its clinical association in autopsies from an ethnically biased …
Proteomic identification and clinicopathologic characterization of splenic amyloidosis
A Chiu, S Dasari, PJ Kurtin, JD Theis… - The American Journal …, 2023 - journals.lww.com
The spleen is a commonly encountered specimen in surgical pathology. However, little is
known about the incidence, morphologic pattern, and clinical features of spleens involved by …
known about the incidence, morphologic pattern, and clinical features of spleens involved by …
Immunohistochemistry and special stains in medical liver pathology
I Clark, MS Torbenson - Advances in anatomic pathology, 2017 - journals.lww.com
Histochemical and immunostains are routinely used to evaluate medical liver biopsy
specimens. The use of these special stains allows the identification of more clinically …
specimens. The use of these special stains allows the identification of more clinically …
LECT2 amyloidosis in kidney transplantation: a report of 5 cases
JM Mejia-Vilet, LR Cárdenas-Mastrascusa… - American Journal of …, 2019 - Elsevier
Leukocyte chemotactic factor 2 (LECT2) amyloidosis is a recently recognized entity that
often affects the kidneys. Little information is available regarding kidney transplant outcomes …
often affects the kidneys. Little information is available regarding kidney transplant outcomes …
An Organ System–Based Approach to Differential Diagnosis of Amyloid Type in Surgical Pathology
G Giannini, CC Nast - Archives of Pathology & Laboratory …, 2020 - meridian.allenpress.com
Context.—Amyloidosis is an uncommon but important entity. A protein-based classification
of amyloidosis defines the underlying disease process, directing clinical management and …
of amyloidosis defines the underlying disease process, directing clinical management and …